Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future Advances in COPD Therapy.

P J Barnes1

  • 1National Heart and Lung Institute, Imperial College School of Medicine, London, UK. p.j.barnes@ic.ac.uk

Respiration; International Review of Thoracic Diseases
|November 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucocorticoid resistance in asthma.

American journal of respiratory and critical care medicine·1995
Same author

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.

The Journal of experimental medicine·1995
Same author

Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.

Molecular pharmacology·1995
Same author

Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages.

The American journal of physiology·1995
Same author

Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction.

Thorax·1995
Same journal

Real-world long-term efficacy of chemoimmunotherapy in advanced stage small cell lung cancer.

Respiration; international review of thoracic diseases·2026
Same journal

Residual AHI Measurement from PAP Devices Versus Home Polygraphy: A Method Comparison Study Using Real World Data.

Respiration; international review of thoracic diseases·2026
Same journal

Unveiling Sex Differences in Severe Acute COPD Exacerbations requiring ICU admission: Evidence from a French Cohort.

Respiration; international review of thoracic diseases·2026
Same journal

Intrapleural Fibrinolytics use in Children with Pleural Empyema: Safe and Effective.

Respiration; international review of thoracic diseases·2026
Same journal

Learning Curve for Transbronchial Lung Cryobiopsy in Interstitial Lung Disease Diagnosis: A Multicenter Experience.

Respiration; international review of thoracic diseases·2026
Same journal

Follow-Up Care After Adult Lung Transplantation: Summary of an Evidence-Based Clinical Practice Guideline for German-Speaking Countries.

Respiration; international review of thoracic diseases·2026
See all related articles

New drug treatments for Chronic Obstructive Pulmonary Disease (COPD) are in development, including novel bronchodilators and anti-inflammatory agents. However, therapies to halt COPD progression are still needed, driving research into new drug targets.

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Drug Discovery

Background:

  • Chronic Obstructive Pulmonary Disease (COPD) requires more effective treatments.
  • Current bronchodilators like tiotropium bromide offer symptomatic relief but do not prevent disease progression.
  • COPD inflammation is often resistant to corticosteroids, necessitating novel anti-inflammatory approaches.

Purpose of the Study:

  • To review emerging drug treatments for COPD.
  • To highlight the need for therapies that can prevent COPD progression.
  • To discuss potential new drug targets identified through advanced research methods.

Main Methods:

  • Review of current and developing COPD pharmacotherapies.
  • Identification of drug classes targeting inflammation and proteolysis.

Related Experiment Videos

  • Exploration of novel therapeutic targets through gene array and proteomics.

    • Main Results:

    • Several new classes of bronchodilators and anti-inflammatory agents are under development.
    • Mediator antagonists (leukotriene B4, chemokine receptor antagonists) and antioxidants are being investigated.
    • Inhibitors of phosphodiesterase-4, nuclear factor-kappaB, p38 MAP kinase, and proteases (neutrophil elastase, matrix metalloproteinase) are in development.

    Conclusions:

    • While new COPD treatments are emerging, therapies to prevent disease progression are critically needed.
    • Ongoing research into mediator antagonists, novel anti-inflammatories, and protease inhibitors shows promise.
    • Gene array and proteomics may reveal future drug targets for COPD management.